Legislation watch

Search all years.

2019 Senate Bill 5380: Concerning opioid use disorder treatment, prevention, and related services
Introduced by Sen. Annette Cleveland (Vancouver) (D) on January 18, 2019
  Official Text and Analysis.
Referred to the Senate Health & Long-Term Care Committee on January 18, 2019
Substitute offered in the Senate on February 8, 2019
Modifies the protocols for using medications to treat opioid use disorder. Permits pharmacists to partially fill certain prescriptions upon patient request. Requires prescribers to discuss the risks of opioids with certain patients and provide the patient with the option to refuse an opioid prescription.
Referred to the Senate Ways & Means Committee on February 11, 2019
Referred to the Senate Rules Committee on February 28, 2019
Received in the House on March 9, 2019
Referred to the House Health Care & Wellness Committee on March 9, 2019
Referred to the House Appropriations Committee on April 3, 2019
Amendment offered by Rep. Eileen Cody (West Seattle) (D) on April 16, 2019
Requires Medicaid and all state regulated plans to provide coverage without prior authorization of at least one federal food and drug administration approved product for opioid use disorder in the drug classes opioid agonists, opioid antagonists, and opioid partial agonists.
The amendment passed by voice vote in the House on April 16, 2019
Amendment offered by Rep. Eileen Cody (West Seattle) (D) on April 16, 2019
Requires the Health Care Authority (HCA) to work with stakeholders to develop a set of recommendations to the Governor and the Legislature that outline strategies to increase the number of waivered health care providers approved for prescribing buprenorphine by the Substance Abuse and Mental Health Services Administration, and to lower the cost of federal Food and Drug Administration approved products for the treatment of opioid use disorder. (2) Removes statements and intent language related to evidence for opioid use disorder medications that patients be provided with a well-coordinated plan of interventions while preserving the patient voice in treatment. (3) Removes duplicative intent language. (4) Removes provisions that state that the HCA must comply with applicable federal law regarding its section 1115 demonstration waiver application. (5) Removes specific permission for the HCA to replicate particular treatment approaches, such as hub and spoke treatment networks.
The amendment passed by voice vote in the House on April 16, 2019
Amendment offered by Rep. Chris Gildon (Puyallup) (R) on April 16, 2019
Prohibits the Health Care Authority from promoting the use of supervised injection sites as a form of treatment for opioid use disorder.
The amendment passed by voice vote in the House on April 16, 2019
Amendment offered by Rep. Morgan Irwin (Enumclaw) (R) on April 16, 2019
Requires the Department of Health to collaborate with health professional and facility associations, electronic health record vendors, and others to comply with federal prescription drug monitoring program qualification requirements under Section 1944 of the federal Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Actto facilitate eligibility for federal grants.
The amendment passed by voice vote in the House on April 16, 2019
Amendment offered by Rep. Drew Stokesbary (Auburn) (R) on April 16, 2019
Prohibits the Health Care Authority from partnering with any agency that supervises the injection of illicit drugs.
The amendment passed 60 to 38 in the House on April 16, 2019.
    See Who Voted "Yes" and Who Voted "No".
Received in the House on April 26, 2019
Received in the Senate on April 26, 2019
Signed by Gov. Jay Inslee on May 8, 2019

Comments